Please check your internet connection and try again.
# Potassium Chloride
## Overview
Potassium chloride (KCl) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous formulations.
## Primary Indications
* Treatment and prevention of hypokalemia.
* Potassium supplementation in patients receiving potassium-depleting medications (e.g., diuretics).
## Adult Dosing
* **Prevention of hypokalemia:** 20-40 mEq daily, divided into 1-2 doses.
* **Treatment of hypokalemia:** 40-100 mEq daily, divided into 2-4 doses. Maximum oral dose typically 20 mEq per dose to minimize GI upset. Intravenous doses vary widely based on severity of hypokalemia and patient status, often guided by institutional protocols and cardiac monitoring. Rapid IV infusion requires extreme caution.
## Pediatric Dosing
* **Oral:** 2-4 mEq/kg/day, divided into 2-4 doses. Maximum daily dose is typically 20-40 mEq for younger children and up to 100 mEq for older children/adolescents, depending on indication and supervision.
* **Intravenous:** Dosing is highly individualized, based on serum potassium levels, body weight, and clinical status. Strict adherence to institutional protocols and continuous cardiac monitoring is crucial. Maximum concentration and infusion rates are critical safety parameters.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Dose reduction is often necessary. Monitor potassium levels closely.
* **Adrenal Insufficiency:** May increase risk of hyperkalemia.
## Contraindications
* Hyperkalemia (serum potassium > 5.0 mEq/L).
* Conditions that predispose to hyperkalemia, such as severe renal impairment, untreated Addison's disease, and certain urinary tract obstructions.
* Known hypersensitivity to potassium chloride.
## Adverse Effects
* **Gastrointestinal (Oral):** Nausea, vomiting, abdominal pain, diarrhea, GI bleeding, ulceration, or perforation (especially with sustained-release formulations or in patients with delayed GI transit).
* **Cardiovascular (IV):** Arrhythmias, cardiac arrest, hypotension.
* **Other:** Hyperkalemia (most serious), paresthesia, muscle weakness, confusion.
## Key Drug Interactions
* **ACE inhibitors, ARBs, Aldosterone antagonists (e.g., spironolactone), Potassium-sparing diuretics (e.g., amiloride, triamterene), NSAIDs, Heparin, Trimethoprim:** Increased risk of hyperkalemia.
* **Diuretics (thiazide, loop):** Can increase potassium loss, necessitating potassium supplementation.
* **Digitalis glycosides:** Hypokalemia enhances digitalis toxicity. Hyperkalemia reduces therapeutic effect.
## Monitoring
* **Serum potassium levels:** Frequently, especially with IV administration or dose adjustments.
* **Renal function (BUN, creatinine):** Periodically.
* **ECG:** Particularly with rapid IV infusion or in patients with pre-existing cardiac conditions.
* **Signs and symptoms of hyperkalemia:** Muscle weakness, paresthesia, arrhythmias.
## Clinical Pearls
* Oral KCl can cause significant GI irritation; administer with food or fluid.
* Sustained-release formulations may cause more GI side effects and should be used cautiously in patients with slow GI transit.
* Intravenous KCl must be administered slowly and diluted appropriately to avoid phlebitis and cardiac arrhythmias. Rapid IV push is dangerous.
* Always confirm the electrolyte content (e.g., mEq/mL) when preparing IV infusions, as concentrations can vary.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant clinical guidelines for the most current and complete drug information, as specific dosing and recommendations may vary.*
